AstraZeneca said on Wednesday that two studies conducted by British and European regulators "reaffirmed" that the benefits of its vaccine "far outweigh the risks" despite finding a possible link to rare blood clots. "Overall, both of these reviews reaffirmed the vaccine offers a high-level of protection against all severities of COVID-19 and that these benefits continue to far outweigh the risks," the British/Swedish company said in a statement. jwp/mjs